KR20010099623A - 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법 - Google Patents
바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법 Download PDFInfo
- Publication number
- KR20010099623A KR20010099623A KR1020017002117A KR20017002117A KR20010099623A KR 20010099623 A KR20010099623 A KR 20010099623A KR 1020017002117 A KR1020017002117 A KR 1020017002117A KR 20017002117 A KR20017002117 A KR 20017002117A KR 20010099623 A KR20010099623 A KR 20010099623A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- furan
- unsubstituted
- oxo
- methylene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9747698P | 1998-08-21 | 1998-08-21 | |
US60/097,476 | 1998-08-21 | ||
US11321298P | 1998-12-22 | 1998-12-22 | |
US60/113,212 | 1998-12-22 | ||
US11932899P | 1999-02-09 | 1999-02-09 | |
US60/119,328 | 1999-02-09 | ||
US13558599P | 1999-05-24 | 1999-05-24 | |
US13558699P | 1999-05-24 | 1999-05-24 | |
US60/135,586 | 1999-05-24 | ||
US60/135,585 | 1999-05-24 | ||
PCT/US1999/018785 WO2000010573A1 (fr) | 1998-08-21 | 1999-08-19 | Composes, compositions et procedes pour traiter des infections virales et les maladies qui y sont liees |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20010099623A true KR20010099623A (ko) | 2001-11-09 |
Family
ID=27536838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017002117A KR20010099623A (ko) | 1998-08-21 | 1999-08-19 | 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1128832A4 (fr) |
JP (1) | JP2002523371A (fr) |
KR (1) | KR20010099623A (fr) |
CN (1) | CN1325309A (fr) |
AU (1) | AU743411B2 (fr) |
BR (1) | BR9913157A (fr) |
CA (1) | CA2341970A1 (fr) |
ID (1) | ID27787A (fr) |
IL (1) | IL141456A0 (fr) |
WO (1) | WO2000010573A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101159000B1 (ko) * | 2010-06-18 | 2012-06-21 | (주) 에빅스젠 | 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200103562T2 (tr) * | 1999-06-10 | 2002-04-22 | Warner-Lambert Company | Amiloid proteini toplanmasını önleme ve amiloid birikintilerini görüntüleme yönteminde kullanım için rodanin türevleri |
CA2383347A1 (fr) | 1999-08-31 | 2001-03-08 | Maxia Pharmaceuticals, Inc. | Benzelidene-thiazolidinediones et leurs analogues, utilises dans le traitement du diabete |
US6727267B2 (en) | 2000-04-05 | 2004-04-27 | Tularik Inc. | NS5B HVC polymerase inhibitors |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
JP5260818B2 (ja) * | 2000-09-29 | 2013-08-14 | ノバルティス・インターナショナル・ファーマシューティカル・リミテッド | 高親和性低分子C5a受容体調節物質 |
BR0207846A (pt) | 2001-03-07 | 2005-09-13 | Incyte San Diego Inc | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas |
JP2004523571A (ja) | 2001-03-08 | 2004-08-05 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Rxr活性化分子 |
GB2376944A (en) * | 2001-05-18 | 2002-12-31 | Pantherix Ltd | Polycyclic heterocyclic compounds and their therapeutic use |
CA2448737C (fr) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Inhibiteurs de polymerase virale |
EP2335700A1 (fr) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic |
AU2002337765A1 (en) | 2001-09-26 | 2003-04-07 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitus c virus |
AU2002352706A1 (en) * | 2001-11-15 | 2003-06-10 | Maxia Pharmaceuticals, Inc. | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
GB2387172A (en) * | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
JP2005535593A (ja) * | 2002-05-17 | 2005-11-24 | キューエルティー インコーポレーティッド | チアゾリジンジチオン誘導体の使用方法 |
PL211889B1 (pl) | 2002-05-20 | 2012-07-31 | Bristol Myers Squibb Co | Pochodna heterocyklosulfonamidowa, kompozycja ją zawierająca oraz ich zastosowanie |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
AU2003301959A1 (en) | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
PL215228B1 (pl) | 2002-05-20 | 2013-11-29 | Bristol Myers Squibb Co | Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie |
CA2489433A1 (fr) | 2002-07-01 | 2004-01-08 | Pharmacia & Upjohn Company Llc | Inhibiteurs de la polymerase ns5b du vhc |
BR0305259A (pt) | 2002-07-01 | 2004-10-05 | Upjohn Co | Inibidores de hcv ns5b polimerase |
FR2845000B1 (fr) * | 2002-09-27 | 2005-05-27 | Oreal | Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute |
BR0314943A (pt) * | 2002-09-30 | 2005-08-02 | Univ California | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes |
US7235573B2 (en) | 2002-09-30 | 2007-06-26 | The Regents Of The University Of California | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors |
AU2003291024A1 (en) * | 2002-11-13 | 2004-06-03 | Rigel Pharmaceuticals, Inc. | Rhodanine derivatives and pharmaceutical compositions containing them |
JP4733023B2 (ja) | 2003-04-16 | 2011-07-27 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルスの大環状イソキノリンペプチド阻害剤 |
WO2005007141A2 (fr) * | 2003-07-11 | 2005-01-27 | Proteologics, Inc. | Inhibiteurs de l'ubiquitine ligase et methodes associees |
FR2858324A1 (fr) * | 2003-07-30 | 2005-02-04 | Centre Nat Rech Scient | Nouveaux composes antibiotiques, compositions pharmaceutiques les contenant et leurs utilisations |
US7112601B2 (en) | 2003-09-11 | 2006-09-26 | Bristol-Myers Squibb Company | Cycloalkyl heterocycles for treating hepatitis C virus |
US7566732B2 (en) | 2003-10-28 | 2009-07-28 | Rigel Pharmaceuticals, Inc. | Rhodanine compositions for use as antiviral agents |
US7026339B2 (en) | 2003-11-07 | 2006-04-11 | Fan Yang | Inhibitors of HCV NS5B polymerase |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
UA86962C2 (en) | 2004-02-20 | 2009-06-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Viral polymerase inhibitors |
RS50815B (sr) | 2004-02-24 | 2010-08-31 | Japan Tobacco Inc. | Kondenzovana heterotetraciklična jedinjenja i njihova upotreba kao inhibitora hcv polimeraza |
US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
CN101189230A (zh) | 2005-05-04 | 2008-05-28 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的杂环化合物 |
CA2608821A1 (fr) * | 2005-06-15 | 2006-12-28 | Shibo Jiang | Compositions antivirales comprenant des phenyl-furanes heterocycliques substitues et composes associes |
US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
CN101437824B (zh) * | 2006-05-04 | 2013-03-13 | 肝炎与病毒研究所 | 用于慢性肝炎病毒治疗的乙型肝炎病毒抗原分泌的抑制剂 |
RS51643B (en) | 2006-10-10 | 2011-10-31 | Medivir Ab. | INHIBITOR HCV NUKLEOZIDA |
WO2008082537A2 (fr) | 2006-12-19 | 2008-07-10 | The General Hospital Corporation | Composés pour moduler l'intégrine cd11b/cd18 |
AU2008271116B2 (en) | 2007-06-29 | 2012-09-20 | Gilead Sciences, Inc. | Antiviral compounds |
CN101801925A (zh) | 2007-06-29 | 2010-08-11 | 吉里德科学公司 | 抗病毒组合物 |
CN101990534A (zh) | 2007-11-01 | 2011-03-23 | Uab研究基金会 | 治疗和预防病毒感染 |
JP2011517313A (ja) | 2007-12-11 | 2011-06-02 | ビアメト ファーマシューティカルズ,インク. | 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤 |
US7947717B2 (en) | 2008-07-18 | 2011-05-24 | Burnham Institute For Medical Research | Inhibitors of lethal factor protease |
KR20110098779A (ko) | 2008-12-03 | 2011-09-01 | 프레시디오 파마슈티칼스, 인코포레이티드 | Hcv ns5a의 억제제 |
BRPI0922366B8 (pt) | 2008-12-03 | 2021-05-25 | Presidio Pharmaceuticals Inc | composto, composição farmacêutica e uso de um composto |
SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
KR20120104239A (ko) | 2009-11-14 | 2012-09-20 | 에프. 호프만-라 로슈 아게 | Hcv 치료에 대한 신속한 반응을 예측하기 위한 바이오마커 |
WO2011067195A1 (fr) | 2009-12-02 | 2011-06-09 | F. Hoffmann-La Roche Ag | Biomarqueurs pour prédire une réponse soutenue à un traitement du vhc |
AU2010336027A1 (en) * | 2009-12-23 | 2012-07-19 | Auckland Uniservices Limited | Compounds, preparations and uses thereof |
US8877707B2 (en) | 2010-05-24 | 2014-11-04 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
US9023876B2 (en) | 2010-07-08 | 2015-05-05 | Adhaere Pharmaceuticals, Inc. | Compounds and methods for regulating integrins |
US9255088B2 (en) | 2010-08-11 | 2016-02-09 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
WO2012123298A1 (fr) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Composés antiviraux |
US20120328565A1 (en) | 2011-06-24 | 2012-12-27 | Brinkman John A | Antiviral compounds |
KR101621181B1 (ko) | 2011-10-10 | 2016-05-13 | 에프. 호프만-라 로슈 아게 | 항바이러스성 화합물 |
CN103987723B (zh) | 2011-12-16 | 2017-03-01 | 弗·哈夫曼-拉罗切有限公司 | Hcv ns5a 的抑制剂 |
ES2626484T3 (es) | 2011-12-20 | 2017-07-25 | Riboscience Llc | Derivados nucleosídicos 4'-azido-3'-fluoro-sustituidos como inhibidores de la replicación del ARN de VHC |
EP2794629B1 (fr) | 2011-12-20 | 2017-05-24 | Riboscience LLC | Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c) |
WO2013124335A1 (fr) | 2012-02-24 | 2013-08-29 | F. Hoffmann-La Roche Ag | Composés antiviraux |
WO2013142346A1 (fr) | 2012-03-23 | 2013-09-26 | The Regents Of The University Of California | Composés de translecture de codons de terminaison prématurés |
WO2013159082A1 (fr) | 2012-04-20 | 2013-10-24 | Adhaere Pharmaceuticals, Inc. | Composés et méthodes pour la régulation d'intégrines |
US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
BR112015017414A2 (pt) | 2013-01-23 | 2017-07-11 | Hoffmann La Roche | derivados de triazol antivirais |
CN105008350B (zh) | 2013-03-05 | 2018-05-08 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒化合物 |
RU2534613C2 (ru) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения |
MA38678A1 (fr) | 2013-05-16 | 2017-07-31 | Riboscience Llc | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués |
SG11201509424VA (en) | 2013-05-16 | 2015-12-30 | Riboscience Llc | 4'-fluor0-2'-methyl substituted nucleoside derivatives |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
KR20200056420A (ko) | 2017-09-21 | 2020-05-22 | 리보사이언스 엘엘씨 | Hcv rna 복제의 억제제로서 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체 |
KR101893988B1 (ko) * | 2018-05-16 | 2018-08-31 | (주)에빅스젠 | 로다닌 유도체를 함유하는 aids 예방 또는 치료용 약학 조성물 |
TW202348228A (zh) | 2022-02-24 | 2023-12-16 | 德商艾斯巴赫生物有限公司 | 病毒組合療法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909467A (en) * | 1958-07-09 | 1959-10-20 | Us Vitamin Pharm Corp | 3-(d-alpha-methylphenethyl)-5-methyl-1, 3-oxazolidine-2, 4-dione |
US3888984A (en) * | 1972-03-13 | 1975-06-10 | Lilly Industries Ltd | Oxazole and imidazole derivatives as antifungal agents |
AU6610081A (en) * | 1980-01-24 | 1981-07-30 | Senju Pharmaceutical Co., Ltd. | Thiazolidine derivatives |
US4367234A (en) * | 1980-07-28 | 1983-01-04 | Pfizer Inc. | Hypoglycemic 5-substituted oxazolidine-2,4-diones |
MX9302578A (es) * | 1992-05-01 | 1994-08-31 | Commw Scient Ind Res Org | Agentes antivirales. |
US5693337A (en) * | 1994-07-13 | 1997-12-02 | Wakamoto Pharmaceutical Co., Ltd. | Stable lipid emulsion |
US5834466A (en) * | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
DE19645974C1 (de) * | 1996-11-07 | 1998-08-13 | Andreas Johannes Kesel | (Z)-5-[[3-Hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methylen]-2-thioxo-4- thiazolidinon, Verfahren zu dessen Herstellung und Verwendung |
-
1999
- 1999-08-19 EP EP99942288A patent/EP1128832A4/fr not_active Withdrawn
- 1999-08-19 KR KR1020017002117A patent/KR20010099623A/ko not_active Application Discontinuation
- 1999-08-19 WO PCT/US1999/018785 patent/WO2000010573A1/fr not_active Application Discontinuation
- 1999-08-19 JP JP2000565894A patent/JP2002523371A/ja active Pending
- 1999-08-19 CN CN99812282A patent/CN1325309A/zh active Pending
- 1999-08-19 ID IDW20010428A patent/ID27787A/id unknown
- 1999-08-19 CA CA002341970A patent/CA2341970A1/fr not_active Abandoned
- 1999-08-19 BR BR9913157-9A patent/BR9913157A/pt not_active Application Discontinuation
- 1999-08-19 AU AU55702/99A patent/AU743411B2/en not_active Ceased
- 1999-08-19 IL IL14145699A patent/IL141456A0/xx unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101159000B1 (ko) * | 2010-06-18 | 2012-06-21 | (주) 에빅스젠 | 신규한 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 aids 예방 또는 치료용 약학 조성물 |
US8759536B2 (en) | 2010-06-18 | 2014-06-24 | Avixgen Inc. | Rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients |
Also Published As
Publication number | Publication date |
---|---|
ID27787A (id) | 2001-04-26 |
AU5570299A (en) | 2000-03-14 |
CN1325309A (zh) | 2001-12-05 |
BR9913157A (pt) | 2001-05-15 |
EP1128832A1 (fr) | 2001-09-05 |
WO2000010573A1 (fr) | 2000-03-02 |
JP2002523371A (ja) | 2002-07-30 |
IL141456A0 (en) | 2002-03-10 |
EP1128832A4 (fr) | 2003-03-05 |
CA2341970A1 (fr) | 2000-03-02 |
AU743411B2 (en) | 2002-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20010099623A (ko) | 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법 | |
US6316492B1 (en) | Methods for treating or preventing viral infections and associated diseases | |
KR20010074949A (ko) | 바이러스성 감염 및 관련 질환의 치료 방법 또는 예방 방법 | |
AU2011205797B2 (en) | Inhibitors of Flaviviridae viruses | |
CN101535303B (zh) | 适合用于治疗与升高的脂质水平有关的疾病的杂环化合物 | |
CN1474803B (zh) | 酰胺衍生物及其制备药物的用途 | |
CN101484449A (zh) | 整合酶抑制剂-3 | |
CN109153640A (zh) | 用抗病毒剂消除乙型肝炎病毒 | |
CN102702193A (zh) | 抗病毒化合物 | |
EP1411052B1 (fr) | Composes heterocycles a 5 chainons condenses avec un benzo, leur procede de preparation et leur utilisation | |
SK15202003A3 (sk) | Tiofénové deriváty ako protivírusové prostriedky pre flavivírusové infekcie | |
KR20090018593A (ko) | 세포괴사 저해제로서의 인돌 및 인다졸 화합물 | |
EP1402900A1 (fr) | Compositions medicinales | |
JP2002537396A (ja) | 抗ウィルス活性を有する[1,8]ナフチリジン誘導体 | |
WO2001007027A2 (fr) | Inhibiteurs d'helicase virale | |
WO2012103113A1 (fr) | Dérivés de pyrazine et d'imidazolidine et leurs utilisations en vue du traitement de l'hépatite c | |
US20020052396A1 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
NZ227287A (en) | 2,5-diaryl tetrahydrofurans and medicaments | |
EP0365089A3 (fr) | 2-Aryl-5(3-méthoxy-5-(hydroxypropylsulphonyl)-4-propoxyphényl) tétrahydrothiophène et analogues | |
US20040198741A1 (en) | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | |
JPH09512548A (ja) | レトロウイルス感染、特にhiv感染の治療のためのメタノール誘導体 | |
CN1809561B (zh) | 苯基乙酰胺及它们作为葡糖激酶调节剂的应用 | |
JP2004515555A (ja) | パピローマウイルス阻害剤 | |
JP2003063993A (ja) | 医薬組成物 | |
EP1844776B1 (fr) | Agent destine a la prevention/au traitement d'une maladie causee par un virus de l'herpes acyclovir-resistant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |